Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IBRUTINIB Cause Electrocardiogram qt prolonged? 27 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 27 reports of Electrocardiogram qt prolonged have been filed in association with IBRUTINIB (Imbruvica). This represents 0.0% of all adverse event reports for IBRUTINIB.

27
Reports of Electrocardiogram qt prolonged with IBRUTINIB
0.0%
of all IBRUTINIB reports
3
Deaths
12
Hospitalizations

How Dangerous Is Electrocardiogram qt prolonged From IBRUTINIB?

Of the 27 reports, 3 (11.1%) resulted in death, 12 (44.4%) required hospitalization, and 4 (14.8%) were considered life-threatening.

Is Electrocardiogram qt prolonged Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IBRUTINIB. However, 27 reports have been filed with the FAERS database.

What Other Side Effects Does IBRUTINIB Cause?

Death (8,007) Off label use (5,446) Fatigue (4,479) Diarrhoea (3,903) Atrial fibrillation (3,671) Pneumonia (3,015) Incorrect dose administered (2,752) Contusion (2,712) Fall (2,375) Asthenia (2,200)

What Other Drugs Cause Electrocardiogram qt prolonged?

QUETIAPINE (1,869) OLANZAPINE (1,325) RIBOCICLIB (1,020) AMIODARONE (1,000) HYDROXYCHLOROQUINE (992) CLOZAPINE (958) CITALOPRAM HYDROBROMIDE (917) ESCITALOPRAM OXALATE (899) ONDANSETRON (881) BUPROPION (853)

Which IBRUTINIB Alternatives Have Lower Electrocardiogram qt prolonged Risk?

IBRUTINIB vs IBUPROFEN IBRUTINIB vs IBUPROFEN LYSINE IBRUTINIB vs IBUPROFEN UNKNOWN PRODUCT IBRUTINIB vs IBUPROFEN\IBUPROFEN IBRUTINIB vs IBUPROFEN\PHENYLEPHRINE

Related Pages

IBRUTINIB Full Profile All Electrocardiogram qt prolonged Reports All Drugs Causing Electrocardiogram qt prolonged IBRUTINIB Demographics